Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec:131:102848.
doi: 10.1016/j.ctrv.2024.102848. Epub 2024 Oct 28.

Local administration of immunotherapy for patients with skin cancer: A systematic review

J C Janssen  1 , B van Dijk  2 , L L Hoeijmakers  3 , D J Grünhagen  4 , W M Bramer  5 , C Verhoef  4 , T D de Gruijl  6 , C U Blank  7 , A A M van der Veldt  8
Affiliations
Free article

Local administration of immunotherapy for patients with skin cancer: A systematic review

J C Janssen et al. Cancer Treat Rev. 2024 Dec.
Free article

Abstract

Since the introduction of immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors, survival has improved significantly for patients with irresectable and metastatic skin cancer, including cutaneous squamous cell cancer and melanoma. However, systemic administration of these drugs is associated with immune related adverse events (irAEs), which can be severe, irreversible and even fatal. To reduce the risk of irAEs associated with systemic exposure to immunotherapeutic drugs, local administration of low doses could be considered. This systematic review provides an overview of early phase clinical trials with drugs that are currently under investigation for intratumoral administration in patients with melanoma and non-melanoma skin cancer.

Keywords: Cutaneous squamous cell cancer; Immunotherapy; Intralesional injection; Local administration; Melanoma; Skin cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [T.D. de Gruijl: Consultancy/advisory board fees (all paid to institute): LAVA Therapeutics, Mendus, GE Health; research support: Idera Pharmaceuticals/Aceragen, BMS, Pfizer, Astra Zeneca; holds stocks from LAVA Therapeutics. C. Blank: Consultancy/advisory board fees (all paid to the institute): Bristol Muyers Squibb, F. Hoffman-La Roche, Merck; Research grants (all paid to the institute) 4SC, Nanostring Technologies; Advisory board fee (individual): Third Rock Ventures A.A.M. van der Veldt: consultancy fees (all paid to the institute): BMS, Eisai, Ipsen, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi. J.C. Janssen none, B. van Dijk none, D.J. Grünhagen none, L.L. Hoeijmakers none, W.M. Bramer none, C. Verhoef none].

Publication types

MeSH terms

Substances

LinkOut - more resources